ADVI’s Lindsay Bealor Greenleaf Discusses President Trump’s Drug Pricing Plan with The Street
Lindsay Bealor Greenleaf, a director at ADVI, a healthcare and life science advisory, praised the Trump administration for wanting to take on the middlemen and being "willing to get down into the weeds on this." She said that the Obama administration wanted to point the finger at drug companies, but Trump is willing to wade into the supply chain, that she called "messy and complicated."
[el-text]
Written by Bill Meagher
***excerpt***
Lindsay Bealor Greenleaf, a director at ADVI, a healthcare and life science advisory, praised the Trump administration for wanting to take on the middlemen and being “willing to get down into the weeds on this.” She said that the Obama administration wanted to point the finger at drug companies, but Trump is willing to wade into the supply chain, that she called “messy and complicated.”
***end excerpt***
***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.